Description
The debate highlighted a critical cell-type specificity gap where no evidence exists for selective microglial targeting of circadian pathways. This fundamental limitation undermines the feasibility of proposed circadian therapies and requires novel delivery mechanisms or microglial-specific drug targeting approaches.
Source: Debate session sess_SDA-2026-04-10-SDA-2026-04-08-gap-debate-20260406-062033-16eccec1 (Analysis: SDA-2026-04-08-gap-debate-20260406-062033-16eccec1)
Resolution criteria
Resolution requires: (1) single-cell RNA-seq of microglia from aged mice (≥18 months) treated with circadian targeter (e.g., logolin, REV-ERB agonist) vs vehicle, showing ≥80% selective gene expression changes in microglia with <20% off-target changes in neurons/astrocytes; (2) circadian phase assay (PER2-luciferase) confirming target engagement in microglia ex vivo; (3) behavioral validation showing cognitive benefit without sleep disruption. Bulk tissue RNA-seq is insufficient due to cell-type confounding.